Norway · Delayed Price · Currency is NOK Orkla ASA Earnings Call Transcripts
Fiscal Year 2026
-
Flat organic revenue and modest EBIT growth were offset by volume declines and currency effects. Jotun's strong performance and recent acquisitions supported EPS growth, but margin pressure and cost headwinds persist, especially from the Middle East conflict.
-
Organic growth reached 4.9% year-over-year, with strong contributions from Food Ingredients, Snacks, and Foods. Adjusted EBIT grew 3%, while input cost pressures and restructuring in Health signal ongoing challenges. Share buybacks and targeted investments continued.
-
The meeting approved strong 2025 financials, a NOK 6 per share dividend, and key board changes. Strategic initiatives included portfolio simplification and the listing of Orkla India. All board, auditor, and remuneration proposals passed, while a shareholder environmental proposal was rejected.
Fiscal Year 2025
-
Q4 saw 4.5% organic growth and 17% EBIT adjusted increase, with all major segments except Foods contributing positively. Jotun and Orkla Snacks delivered strong profit growth, while inflation and competitive pressures remain key risks.
-
Q3 saw 4.4% organic growth, 9% EPS increase, and NOK 17.9B revenue. Portfolio companies showed mixed performance, with Jotun and Orkla India as key contributors. A NOK 4B share buyback was announced, and raw material costs are expected to stabilize in 2025.
-
Organic growth reached 3.8% with strong performance in Fuel Ingredients and Home & Personal Care, while Health and Snacks faced margin pressures from high input costs. Portfolio simplification and a potential India IPO progressed, with EBIT margin and return on capital employed both improving.
-
Delivered strong TSR and financial improvements, reduced portfolio complexity, and advanced strategic priorities for organic growth, simplification, and targeted M&A. Portfolio companies are on track for 2026 targets, with operational enhancements and ESG progress supporting long-term value creation.
-
Solid quarterly results with 2% revenue growth, 10% EBIT (adjusted) increase, and 19% higher EPS year-over-year. Margin improvements were broad-based, though snacks and foods faced volume declines due to high cocoa prices and transitory effects. Portfolio simplification and investments in growth continued.
Fiscal Year 2024
-
Strong EBIT and cash flow growth in 2024, driven by portfolio simplification, margin improvements, and stable market shares. Cocoa price volatility and asset sales shaped the quarter, with a proposed NOK 10 per share dividend reflecting robust performance.
-
Q3 delivered strong profit and margin growth, with adjusted EPS up 10% and EBIT up 17% year-over-year. Organic growth was broad-based, cash flow improved, and key segments like Jotun and Orkla Health outperformed, despite inflation and cocoa price pressures.
-
Q2 saw 7% EPS growth and 13% EBIT Adjusted growth, with strong margin expansion and positive volume trends across most segments. Portfolio simplification advanced with asset sales, while input costs and private label competition remain key watchpoints.